In addition, MT administration reduced the expression of HFD-induced lipid accumulation-related transcription factors and their target genes, including Mlxipl, Srebf1, Srebf2, Fas, Acc2, Scd1, Scd2, Gpam, Dgat1, and Dgat2. Thus, treatment with arazyme improved HFD-induced hepatic steatosis by inhibiting the expression of lipogenic genes and proteins. This evidence concerns the gene FAS and fatty liver disease.